A Single-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Intravenously Infused GSK1070806 in Healthy and Obese Subjects.
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2017
At a glance
- Drugs GSK 1070806 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jan 2011 Planned end date changed from 1 Nov 2010 to 1 Jul 2011 as reported by ClinicalTrials.gov.